Dr. B. Douglas Smith
            CML - Chronic myeloid leukemia

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore

VIDEOS

First- and Second-Line Nilotinib in CML
January 14, 2015, OncLive
​

ARTICLES

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
November 2019, Science Direct
 
Imatinib for Chronic Myeloid Leukemia: The Impact of Its Effectiveness and Long-term Side Effects
March 21, 2011, Oxford Academic
​